How similar are states' medicaid preferred drug lists?

American Journal of Managed Care

Volumn 14, Issue 11 SPEC. ISS., 2008, Pages

  Ketcham, Jonathan D ^a   Ngai, Jeffrey K ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DECISION MAKING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; MEDICAID; PRIORITY JOURNAL; UNITED STATES;

FORMULARIES AS TOPIC; HUMANS; MEDICAID; PRESCRIPTION DRUGS; STATE HEALTH PLANS; UNITED STATES;

EID: 56749101658     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Simon K, Tennyson S, Hudman J. What policies are states using to control Medicaid prescription drug spending during 1990-2004, and how effective are they? Risk Management and Insurance Review. In press.
2. Virabhak S, Shinogle J. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11(1 Spec No.):SP14-SP20.
3. Murawski M, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care. 2005;11(1 Spec No.):SP35-SP42.
4. Lichtenberg F. The effect of access restriction on the vintage of drugs used by Medicaid enrollees. Am J Manag Care. 2005;11(1 Spec No.):SP7-SP13.
5. Lichtenberg F. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood). 2001;20(5):241-251.
6. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11(1 Spec No.):SP28-SP34.
7. Ketcham JD, Epstein AJ. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives? Pharmacoeconomics. 2006;24(suppl 3):27-40.
8. Ketcham JD, Epstein AJ. Medicaid preferred drug lists' costs to physicians. Med Care. 2008;46(1):9-16.
9. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2008;23(1):124-134.
10. Berk M, Schur C, Gupta J. Insights into Formulary Decision Processes: Findings from a National Survey of Health Plans. Silver Spring, MD: Social & Scientific Systems, Inc; March 2008. http://www.fmcpnet.org/ cfr/waSys/f.cfc?method=getListFile&id=3EE4422A. Accessed September 8, 2008.
11. Oregon Health & Science University. Drug Effectiveness Review Project (DERP). http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/. Accessed August 27, 2008.
12. Moore WJ, Newman RJ. Drug formulary restrictions as a cost-containment policy in Medicaid programs. J Law Econ. 1993;36:71-97.
13. Dranove D, Hughes EF, Shanley M. Determinants of HMO formulary adoption decisions. Health Serv Res. 2003;38(1, pt 1):169-190.
14. Neumann PJ, Lin PJ, Greenberg D, et al. Do drug formulary policies reflect evidence of value? Am J Manag Care. 2006;12(1):30-36.
15. Crowley JS, Ashner D, Elam L. State Medicaid Outpatient Prescription Drug Policies: Findings from a National Survey, 2005 Update. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2005:1-64. Henry J. Kaiser Family Foundation Report 7381.
16. Wolters Kluwer Health. Source* Pharmaceutical Audit Suite Tool. http://www.wkhealth.com/pt/re/ps/source.htm. Accessed October 20, 2008.
17. National Conference of State Legislatures. Pharmaceutical Bulk Purchasing: Multi-state and Inter-agency Plans, 2008 edition. Updated August 13, 2008. http://www.ncsl.org/programs/health/bulkrx.htm. Accessed August 27, 2008.
18. Health and Human Services Commission. Analysis of Multi-state Medicaid Drug Purchasing Pool. http://www.hhsc.state.tx.us/reports/Multi- State_MedicaidDrugPurchasing.pdf. Accessed August 27, 2008.
19. Tomalik-Sharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 2008;8(1):4-15.
20. Mangravite LM, Thom CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006;6(6):360-374.
21. Tseng CW, Mangione CM, Brook RH, Keeler E, Dudley RA. Identifying widely covered drugs and drug coverage variation among Medicare Part D formularies. JAMA. 2007;297(23):2596-2602.
22. Huskamp HA, Rosenthal MB, Frank RG, Newhouse JP. The Medicare prescription drug benefit: how will the game be played? Health Aff (Millwood). 2000;19(2):8-23.